NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!

Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.

Start Free »

ZBIO | NASDAQ

$27.96 $0.99 | 3.67%

SIGNAL:

|2026-09-23 |F&G 39 |RSI 34.4

Add to favoritesFavorite

Company Overview:

Market Cap: $1.76B

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $13.50 - $44.60

2 Year ZBIO Performance Metrics:

Total Return (with DRIP): 55.6% (24.74% CAGR)

Total Return (no DRIP): 55.6% (24.74% CAGR)

Share Price: 55.6% (24.74% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $15,559

Total Return $ (with DRIP): $5,559

ZBIO Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

ZBIO Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

ZBIO Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

ZBIO - Revenue

ZBIO Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ZBIO - Earnings Per Share (EPS)

ZBIO EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ZBIO - Net Income

🔓 See the full chart40% off right now · 7-day free trial

ZBIO Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ZBIO - EBITDA

🔓 See the full chart40% off right now · 7-day free trial

ZBIO EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ZBIO - Free Cash Flow

🔓 See the full chart40% off right now · 7-day free trial

ZBIO Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ZBIO - Free Cash Flow / Share

🔓 See the full chart40% off right now · 7-day free trial

ZBIO Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ZBIO - Operating Income

🔓 See the full chart40% off right now · 7-day free trial

ZBIO Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ZBIO - Gross Profit

🔓 See the full chart40% off right now · 7-day free trial

ZBIO Gross Profit CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ZBIO - Shares Outstanding

🔓 See the full chart40% off right now · 7-day free trial

ZBIO Shares Outstanding CAGR:1Y: 50.75%2Y: 28.34%5Y: 0.00%10Y: 0.00%

ZBIO - Share Buybacks

🔓 See the full chart40% off right now · 7-day free trial

ZBIO Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ZBIO - Stock-Based Comp

🔓 See the full chart40% off right now · 7-day free trial

ZBIO Stock-Based Comp CAGR:1Y: 42.58%2Y: 136.88%5Y: 0.00%10Y: 0.00%

ZBIO - Expenses

🔓 See the full chart40% off right now · 7-day free trial

ZBIO Expenses CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ZBIO - Revenue vs Net Income

🔓 See the full chart40% off right now · 7-day free trial

ZBIO - EPS vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

ZBIO - EPS vs PE Ratio

🔓 See the full chart40% off right now · 7-day free trial

ZBIO - FCF vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

ZBIO - FCF vs Stock Based Comp

🔓 See the full chart40% off right now · 7-day free trial

ZBIO - Cash & Debt

🔓 See the full chart40% off right now · 7-day free trial

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

ZBIO - REVENUE: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

ZBIO Actual Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ZBIO - EPS: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

ZBIO Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ZBIO - NET INCOME: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

ZBIO Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ZBIO - EBITDA: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

ZBIO Actual EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

ZBIO - Net Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

ZBIO Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ZBIO - Gross Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

ZBIO Gross Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ZBIO - Price to Earnings

🔓 See the full chart40% off right now · 7-day free trial

ZBIO Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ZBIO - Price To Sales Ratio

🔓 See the full chart40% off right now · 7-day free trial

ZBIO Price To Sales Ratio CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ZBIO - Return on Capital Employed

🔓 See the full chart40% off right now · 7-day free trial

ZBIO Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ZBIO - Return on Invested Capital

🔓 See the full chart40% off right now · 7-day free trial

ZBIO Return on Invested Capital CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Projected Future Returns & Dividends for ZBIO

Based on past 2-year performance, here are ZBIO growth metrics:

Share price CAGR of +24.74%
Dividend CAGR of +0%

Using ZBIO CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	ZBIO (DRIP)	ZBIO - No DRIP
Current Price	$27.96	$27.96
Start Shares	357.65	357.65
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	357.65	357.65
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$27.96	$27.96
Total Dividends	$0	$0
Final Value	$10,000	$10,000

Estimated Future Value + Dividends - ZBIO

NOTE: Above numbers are our estimate based on ZBIO's Dividend and Price CAGR over past 2 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

Zenas BioPharma, Inc. (ZBIO) had its IPO on 2024-09-13, and is traded on NASDAQ stock exchange.

Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.

ZBIO website: https://zenasbio.com

Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

DCF Model — ZBIO

Value from:

EPS (TTM)icompany profit per share over the last 12 months

EPS Growth %ihow fast profit per share grows each of the next 5 years — prefilled with what analysts expect

EPS growth after year 5 (forever)ithe slower pace once the fast 5 years are over — only drives years 6-10 of the price path below

Exit multiple (PE in 5 yrs)iwhat buyers pay per $1 of profit in 2031 — prefilled with today’s forward PE

Desired return %/yrithe yearly return you want from buying today — the S&P has done ~14%/yr, ask for more from a single stock

FCF growth %/yr (next 5 yrs)ihow fast free cash flow grows while the company is still expanding fast

Years of fast FCF growthihow many years the fast growth lasts before the business settles down

FCF growth after year 5 (forever)ithe slow, steady pace once the company is mature — usually 2-3%, near inflation. Must stay below your target return

Risk-free rate %iwhat a 10-yr US treasury pays with zero risk — the floor any risky stock must beat

Your target return %/yrithe yearly return you want for taking this risk — rule of thumb: risk-free rate + extra for risk

FCF base ($M, TTM)ilast 12 months of free cash flow, added up from reported quarters

Include dividends in returnidividends hand you part of the return in cash, so the share price needs to climb less

Pay up to today

—

vs current price $27.96

—

Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today

—

grows for the next years

Then mature

—

every future dollar counted back to today

Pile of today-dollars

—

÷ shares

Implied price path

Year	FCF	Implied price

Sensitivity — fair value: growth ↓ × target return →